

1 **Efficacy of the low level laser therapy (LLLT) on hair regrowth in**
2 **dogs with non-inflammatory alopecia: a pilot study.**

3
4 **Lara Olivieri*, Damiano Cavina*, Giada Radicchi†, Vincenzo**
5 **Miragliotta‡, Francesca Abramo‡**

6
7 **Clinica Veterinaria Modena Sud, Spilamberto, Italy*

8 *† Private practitioner - Biotechnologist, Massa, Italy, Italy*

9 *‡Department of Veterinary Sciences, University of Pisa, Pisa, Italy*

10
11
12 **Acknowledgements**

13 Authors would like to thank Chiara Noli for critical review of the manuscript.

14
15
16
17 Corresponding author

18 Vincenzo Miragliotta, DVM, PhD

19 Assistant Professor – University of Pisa

20 Dept. of Veterinary Sciences

21 Viale delle Piagge 2, 56124 – Pisa

22 Tel. +39-050-2216865

23 Fax +39-050-2216868

24 vincenzo.miragliotta@unipi.it

25
26
27
28 Source of funding: none

29
30 Conflict of interest: none declared

31
32 Short running title: Laser therapy and canine alopecia

33
34
35
36
37
38
39

40 Abstract

41

42 **Background** – Canine non-inflammatory alopecia (CNA) is a heterogeneous
43 group of skin disease of dogs **with different underlying** pathogeneses. The
44 therapeutic approach is challenging and new options for the treatment would
45 be desirable.

46

47 **Hypothesis/Objectives** – To test the clinical efficacy of low level laser
48 therapy (LLLT) on hair regrowth in CNA.

49

50 **Animals** – **Seven** dogs of different age, breeds and genders with a clinical
51 and histopathological diagnosis of non-inflammatory alopecia.

52

53 **Methods** – Each dog was treated twice weekly for a maximum of two
54 months with a therapeutic laser producing three different wavelengths:
55 13x16mW-470nm, 4x50mW-685nm and 4x200 mW-830nm. Fluence given
56 was 3 J/cm², with a frequency of 5 Hz, amplitude on an irradiated area of 25
57 cm² and application time of 1,34 minutes. A predetermined alopecic area was
58 left untreated and served as a control. From one dog a post-treatment
59 biopsy from treated and untreated sites was obtained to histologically
60 evaluate the hair density and the percentage of haired and non-haired
61 follicles.

62

63 **Results** – At the end of the study coat regrowth was highly improved in 6/7
64 animals and improved in 1/7. By morphometry the area occupied by hair
65 follicles was higher in the treated sample (18%) compared to the untreated
66 one (11%); haired follicles were (per area) 93% in the treated sample and
67 only 9% in the control.

68

69 **Conclusions and clinical importance** – Our clinical and histological data
70 documents promising effects of LLLT on hair regrowth in CNA. Further
71 studies investigating the biological mechanism underlying the effect of LLLT
72 on hair follicle cycling are warranted.

73

74

75 Introduction

76

77 Canine non-inflammatory alopecia (CNA) is a clinical presentation which
78 encompasses skin diseases characterized by loss of hair for underlying
79 dysplastic, functional (hair cycling) or endocrine disorders: follicular
80 dysplasia, pattern **alopecia**, recurrent flank alopecia, hair cycle arrest, post
81 clipping alopecia, hypercorticism or hypothyroidism are some of them¹.
82 Diagnosis of these conditions relies on the history, clinical and laboratory
83 findings and histopathology. A correct histological detection of the well
84 known morphological features² of the normal cycling follicle is indeed
85 essential for the identification of different patterns that can be classified as
86 CNA³. Besides anagen, telogen and catagen a new phase called kenogen was
87 recently described in dogs: this indicates hair follicles (HFs) that remained
88 empty after losing their hair shaft and before a new anagen phase is
89 initiated³. The number of kenogen follicles was increased in all 76 patients
90 with CNA included in a recent study³ where authors concluded that anagen
91 induction was impaired due to either a lack of stimuli or a defect in the
92 progenitor cells activation³.

93 In spite of these hypotheses many aspects of the pathogenesis underlying
94 the hair follicle cycling impairment is still unrevealed and the therapeutic
95 approach is thus challenging³. Off-label therapies are indeed still attempted
96 for the treatment of CNA with either poor results or unwanted side effects.
97 Since Albert Einstein in 1917 first described the concept of laser (Light
98 Amplification by Stimulated Emission of Radiation), the first cutaneous
99 applications for skin pathologies date back to the sixties⁴. Several studies in
100 human medicine suggest the use of low power lasers and light therapies for
101 the treatment of some forms of non-inflammatory alopecia⁵, particularly
102 androgenetic alopecia^{6,7} and alopecia areata^{8,9}.

103 The idea for the study emerged from the clinical observation by one of the
104 author (LO) of fast hair regrowth in a clipped coxo-femoral region of a dog
105 receiving low level laser therapy (LLLT) as antalgic treatment. Thus, we
106 tested the clinical efficacy of LLLT on hair regrowth in **seven** cases of CNA.
107 **LLLT expose cells to low levels of red and near infrared light and its**
108 **energy density is low compared to other forms of laser treatments**
109 **(i.e.High Level Laser Treatment-HLLT) that use laser power to induce**
110 **a photothermal damage on target tissue and are used in many**
111 **surgical fields for ablation and cutting^{8,9}.**

112 **Low levels of light is thoughts to induce a photochemical interaction**
113 **with cellular chromophores and evidence exists that the**
114 **chromophore is the mitochondrial cytochrome c oxidase (CCO). The**
115 **result of the excited state of CCO is an increase in the production of**
116 **ATP and ROS which ultimately act as signalling molecules which**
117 **promote cell cycle progression, enzyme activation, nucleic acid and**
118 **protein synthesis⁸. Despite a detailed mechanism of action is still**
119 **under investigation and its clinical application is pioneering for**
120 **human as well as veterinary medicine, the authors believe LLLT**
121 **would represent a new treatment option for hair regrowth in CNA.**
122

123 Materials and Methods

124

125 Inclusion criteria - Dogs with one or more alopecic areas on the body were
126 included. Patients were subjected to a pre-inclusion examination: screening
127 exams included a complete haematology and clinical chemistry profile
128 including thyroidal and adrenal hormones (in order to exclude
129 hypothyroidism and Cushing syndrome), skin scraping, wood lamp
130 examination, trichogramme and fungal cultures. Written consent was
131 obtained from the owners of all dogs.

132

133 Histological examinations and morphometry - A pre-treatment biopsy was
134 obtained as control specimen and to confirm the clinical diagnosis of non-
135 inflammatory alopecia from all dogs.

136 Biopsies underwent formalin fixation and paraffin embedding (FFPE) following
137 the routine methods. The histopathological diagnosis was performed on
138 Haematoxylin & Eosin (H&E) stained 5 μ m sections.

139 From one dog (case N° 5), a post-treatment biopsy from both treated and
140 untreated sites was obtained for the histological and morphometrical analysis
141 of follicular units. Transverse sections at the isthmus level were obtained and
142 stained with H&E and Mallory's trichrome and were considered representative
143 of the isthmus region if sebaceous glands were present. Morphometrical
144 parameters evaluated in this single dog included percent of measured area
145 occupied by hair follicles and percent of haired and non-haired follicles.

146

147 LLLT treatment - After inclusion, each dog was treated twice weekly for a
148 maximum of two months with a type BTL 4000® (BTL Italia Srl, Salerno,
149 Italy) therapeutic laser with a cluster probe producing three different
150 wavelengths emerging simultaneously from 21 foci: 13x16mW (470nm),
151 4x50mW (685nm) and 4x200 mW (830nm) (Fig 1).

152 Fluence given at each therapeutic session was 3 J/cm², with a frequency of 5
153 Hz, amplitude on an irradiated area of 25 cm² and application time of 1,34
154 minutes.

155 The laser probe was kept at a definite distance from the alopecic area (< 2
156 cm) and was continuously moved back and forth on the skin surface to fully
157 cover the entire lesion. In dogs with only one alopecic lesion a predetermined
158 portion was left untreated. When multifocal alopecia was present, treated
159 and control areas were pre-determined: when alopecia was bilateral, one
160 side was treated and the contralateral served as control; in other cases

161 treated and non treated areas were pre-determined assuring that no
162 irradiation was given to control areas.
163 Neither pharmacological treatments nor food restriction was given to the
164 patients during the study.

165
166 LLLT effect assessment – LLLT efficacy was clinically assessed in all dogs by
167 visual examination of the animal and written recording of the status in
168 comparison with the previous examination. Areas were photographically
169 documented at the beginning of the study, after eight treatments (four
170 weeks) and at the end of the study; pictures served to grade alopecic areas
171 as: “unchanged.”, “worsened”, “improved”, “highly improved”.

172
173

174 Results

175
176 **Seven** dogs of different age and breed with clinical and histological diagnosis
177 of CNA were included in the study. Patient data are reported in table 1.

178
179 No case showed inflammatory cell infiltrate at the histological examination.
180 Cases n. **5** and **7** showed signs of recurrent flank alopecia (severe
181 infundibular hyperkeratosis in enlarged infundibula, presence of kenogen
182 follicles, and epidermal multifocal marked hyperpigmentation). Cases n. **1**
183 and **2** were diagnosed with post clipping alopecia (haired telogen with
184 prominent trichilemmal keratinization). Cases n. **3, 4 and 6** showed no
185 specific histological **change but the presence of small hair follicles thus**
186 **corroborating the clinical diagnosis of pattern alopecia.**

187
188 **All enrolled** dogs ended the study: 4/7 received 16 laser treatments (cases
189 n. **1, 4, 5, 6**) and 3/7 only 10 (cases n. **2, 3, 7**). At the end of the study, in
190 6/7 animals (cases n. **1, 2, 4, 5, 6, 7**) the coat quality was highly improved
191 (Fig. 2, 3, 4) while in 1/7 (case nos. **3**) it was graded as improved.
192 On the biopsy specimen taken from case n. **5** at the end of the study,
193 longitudinal sections showed recovery of the histological signs related to
194 recurrent flank alopecia only in the treated side. Transverse sections allowed
195 to distinguish the triplet assembling of canine follicle units. While the
196 majority of hair follicles in the non-treated side of these sections were
197 kenogen (absence of hair shaft, lumen collapsing either with or without
198 trichilemmal keratin) a remarkable presence of haired follicles was visible in
199 the treated sample (Fig. 5).
200 Histomorphometry showed changes in both considered parameters: percent
201 of area occupied by hair follicles was higher (18%) in the treated sample
202 compared to the untreated one (11%); haired follicles were (per area) 93%
203 in the treated sample and only 9% in the control.

204

205

206 Discussion

207

208 LLLT is widely used in veterinary medicine and its efficacy is reported in
209 various conditions¹⁰ but not alopecic disorders. LLLT has shown beneficial
210 effects for a variety of human clinical conditions including several types of
211 hair loss^{6,11}. To the author's knowledge, this is the first study that evaluates
212 clinical efficacy of LLLT in dogs affected with non-inflammatory alopecia.

213 Our data indicate that LLLT is an effective and safe option for treating CNA,
214 since a positive effect was visible in 100% of subjects that ended the study
215 and a dramatic improvement in the recovery of the coat was obtained in 6/7
216 animals (85.7%). This might be of remarkable importance since current
217 pharmacological treatment of CNA relies on the administration of minoxidil¹,
218 finasteride¹² or melatonin^{13,14}, off label therapies that might lead to
219 unwanted side-effects¹⁴⁻¹⁶. The clinical (all dogs) and morphometrical (one
220 dog) evaluation of the untreated sites, which remained unchanged, allowed
221 to exclude spontaneous hair regrowth as hypothesized for some of the CNA,
222 particularly for cycling flank alopecia¹⁷.

223 The phenomenon of paradoxical hypertrichosis and our observation of hair
224 regrowth in the alopecic coxo-femoral region recalled the experience of
225 Endre Master who, in the late 1960, improved hair regrowth on the shaved
226 back of mice by using a low-power ruby laser while his intention was to
227 induce carcinogenesis¹⁸.

228 Since then most studies investigating the effects of LLLT on hair regrowth
229 have used wavelengths ranging from 500 to 1100 nm (red and near-infrared
230 spectrum) with delivered fluencies of 1-10 J/cm² and a power density of 3-
231 90mW/cm⁶.

232 Among physical parameters that can be managed when using LLLT devices,
233 fluence (the energy dose administered on the surface unit) probably plays a
234 major biological role¹⁹. In our study we used a fluence of 3J/cm² following
235 the manufacturer instructions and we are not able to hypothesize whether
236 lower or higher values would have influenced the clinical efficacy.

237 Despite in 2007 and 2011 FDA approved LLLT as a safe treatment for male
238 and female pattern hair loss respectively²⁰, the exact mechanism of action of
239 LLLT in hair growth is not known⁶. Laser phototherapy is assumed to
240 stimulate anagen phase re-activation in telogen hair follicles and increase the
241 degree of proliferation in active anagen hair follicles together with preventing
242 catagen development^{20,21}.

243 Moreover it has been reported that sub-therapeutic fluences at the periphery
244 of treated areas can induce terminal differentiation of hair growth rather than
245 the wanted miniaturization, probably because instead of entering prolonged
246 telogen phase, follicles are shifted towards terminal anagen hair growth²².

247 Transverse sections through the isthmus area have allowed, even if in only
248 one case, to determine the presence of kenogen follicles in the alopecic
249 areas: this would have been more difficult in longitudinal sections due to the
250 thickness of the follicle itself. The absence of the hair inside the lumen and
251 the collapse of the wall in the mid-portion of the follicle is unequivocal for the
252 diagnosis of the kenogen state.

253 In conclusion our study documents promising effect of LLLT on hair
254 regrowth; due to its clinical nature, our study does not allow to hypothesise
255 any mechanism whereby LLLT can induce hair regrowth in dogs with non-
256 inflammatory alopecia; further investigations are thus needed to establish
257 the cellular and molecular mechanisms for the growth-promoting effect of
258 LLLT in dogs. **Also, our study will need to be corroborated by a larger
259 placebo-controlled trial.**

260

261 References

262

263 1. Mecklenburg L, Linek M, Tobin DJ. *Hair loss disorders in domestic animals*. Ames, Iowa,
264 USA: John Wiley & Sons, 2009.

265 2. Muntener T, Doherr MG, Guscetti F, et al. The canine hair cycle - a guide for the
266 assessment of morphological and immunohistochemical criteria. *Vet Dermatol* 2011;22:383-395.

267 3. Muntener T, Schuepbach-Regula G, Frank L, et al. Canine noninflammatory alopecia: a
268 comprehensive evaluation of common and distinguishing histological characteristics. *Vet Dermatol*
269 2012;23:206-e244.

270 4. Goldman L, Blaney DJ, Kindel DJ, Jr., et al. Effect of the laser beam on the skin.
271 Preliminary report. *J Invest Dermatol* 1963;40:121-122.

272 5. Rangwala S, Rashid RM. Alopecia: a review of laser and light therapies. *Dermatol Online J*
273 2012;18:3.

274 6. Avci P, Gupta GK, Clark J, et al. Low-level laser (light) therapy (LLLT) for treatment of hair
275 loss. *Lasers Surg Med* 2014;46:144-151.

276 7. Avram MR, Rogers NE. The use of low-level light for hair growth: part I. *J Cosmet Laser*
277 *Ther* 2009;11:110-117.

278 8. Chung H, Dai T, Sharma SK, et al. The nuts and bolts of low-level laser (light) therapy. *Ann*
279 *Biomed Eng* 2012;40:516-533.

280 9. Kim WS, Calderhead RG. Is light-emitting diode phototherapy (LED-LLLT) really effective?
281 *Laser Ther* 2011;20:205-215.

282 10. Bartels KE. Lasers in veterinary medicine--where have we been, and where are we going?
283 *Vet Clin North Am Small Anim Pract* 2002;32:495-515.

284 11. Metelitsa AI, Green JB. Home-use laser and light devices for the skin: an update. *Semin*
285 *Cutan Med Surg* 2011;30:144-147.

286 12. Cerundolo R. Symmetrical alopecia in the dog. *In Practice* 1999;21:350-359.

287 13. Diaz SF, Torres SM, Nogueira SA, et al. The impact of body site, topical melatonin and
288 brushing on hair regrowth after clipping normal Siberian Husky dogs. *Vet Dermatol* 2006;17:45-50.

289 14. Paradis M. Melatonin therapy in canine alopecia In: Bonagura J, ed. *Kirk's Current*
290 *Veterinary Therapy*. Philadelphia: W.B. Saunders, 1999;546-548.

291 15. Iguer-Ouada M, Versteegen JP. Effect of finasteride (Proscar MSD) on seminal
292 composition, prostate function and fertility in male dogs. *J Reprod Fertil Suppl* 1997;51:139-149.

293 16. Mesfin GM, Higgins MJ, Robinson FG, et al. Relationship between Serum Concentrations,
294 Hemodynamic Effects, and Cardiovascular Lesions in Dogs Treated with Minoxidil. *Toxicology and Applied*
295 *Pharmacology* 1996;140:337-344.

296 17. Tobin D, Gardner S, Luther P, et al. A natural canine homologue of alopecia areata in
297 humans. *British Journal of Dermatology* 2003;149:938-950.

298 18. Mester E, Szende B, Gartner P. [The effect of laser beams on the growth of hair in mice].
299 *Radiobiol Radiother (Berl)* 1968;9:621-626.

300 19. Tuner J, Hode L. *The new laser therapy handbook: a guide for research scientists, doctors,*
301 *dentists, veterinarians and other interested parties within the medical field*. Grängesberg: Prima Books,
302 2010.

303 20. Wikramanayake TC, Rodriguez R, Choudhary S, et al. Effects of the Lexington LaserComb
304 on hair regrowth in the C3H/HeJ mouse model of alopecia areata. *Lasers Med Sci* 2012;27:431-436.

305 21. Leavitt M, Charles G, Heyman E, et al. HairMax LaserComb laser phototherapy device in
306 the treatment of male androgenetic alopecia: A randomized, double-blind, sham device-controlled,
307 multicentre trial. *Clin Drug Investig* 2009;29:283-292.

308 22. Willey A, Torrontegui J, Azpiazu J, et al. Hair stimulation following laser and intense
309 pulsed light photo-epilation: review of 543 cases and ways to manage it. *Lasers Surg Med* 2007;39:297-
310 301.

311

312

313

314 Legends for figures

315

316 Figure 1: Therapeutic laser and its cluster probe (inset).

317

318 Figure 2: Clinical photographs case no **5**; Recurrent Flank Alopecia in a
319 neutered female Lagotto; a, b) pretreatment photographs; c) untreated area
320 after 4 treatments; **d**) treated area after 4 treatments; e) follow-up after 10
321 months from the end of study of the untreated area; f) follow-up after 10
322 months from the end of study of the treated area.

323

324 Figure 3: Clinical photographs case no **6**; ear Pattern **alopecia** in a male
325 **Deutsch Kurzhaar**; a & b) ears at the beginning of the study; c & d)
326 untreated and treated ear at the end of the study, respectively.

327

328 Figure 4: Clinical photographs case no **7**; Recurrent Flank Alopecia in a
329 neutered female Boxer; a & b) alopecic areas at the beginning of the study;
330 c & d) untreated and treated areas at the end of the study, respectively.

331

332 Figure 5: microphotographs of transverse sections through the isthmus from
333 case no **5** at the end of the study; a & c) low magnification of the untreated
334 and treated areas respectively; b & d) higher magnification of the untreated
335 and treated areas respectively; arrector pili muscle (*) and sebaceous glands
336 (arrowhead) are shown. The majority of follicles are kenogen in the
337 untreated area (b) while they are anagen in treated one (d). a & c: scale bar
338 = 1 mm; b & d: scale bar = 100 μm .

339

340

341